These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 33337478)

  • 1. Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis.
    Lee MMY; Docherty KF; Sattar N; Mehta N; Kalra A; Nowacki AS; Solomon SD; Vaduganathan M; Petrie MC; Jhund PS; McMurray JJV
    Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):165-178. PubMed ID: 33337478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities.
    Patoulias D; Katsimardou A; Stavropoulos K; Imprialos K; Kalogirou MS; Doumas M
    Curr Hypertens Rep; 2020 Sep; 22(11):90. PubMed ID: 32910274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Review and Meta-Analysis.
    Chan CK; Huang YS; Liao HW; Tsai IJ; Sun CY; Pan HC; Chueh JS; Wang JT; Wu VC; Chu TS;
    Hypertension; 2020 Nov; 76(5):1563-1571. PubMed ID: 32869673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
    Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
    JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis.
    Tleyjeh IM; Bin Abdulhak AA; Tlayjeh H; Al-Mallah MH; Sohail MR; Hassett LC; Siller-Matula JM; Kashour T
    Am J Ther; 2020 Dec; 29(1):e74-e84. PubMed ID: 33395057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: A meta-analysis.
    Zhang G; Wu Y; Xu R; Du X
    J Med Virol; 2021 Apr; 93(4):2287-2300. PubMed ID: 33231299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.
    Loader J; Taylor FC; Lampa E; Sundström J
    J Am Heart Assoc; 2022 Jun; 11(11):e025289. PubMed ID: 35624081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials.
    Lee MMY; Kondo T; Campbell RT; Petrie MC; Sattar N; Solomon SD; Vaduganathan M; Jhund PS; McMurray JJV
    Eur Heart J Cardiovasc Pharmacother; 2024 Jan; 10(1):68-80. PubMed ID: 37740450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension.
    Lee J; Jo SJ; Cho Y; Lee JH; Oh IY; Park JJ; Cho YS; Choi DJ
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S123-S131. PubMed ID: 32872731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.
    Chu C; Zeng S; Hasan AA; Hocher CF; Krämer BK; Hocher B
    Br J Clin Pharmacol; 2021 Jun; 87(6):2475-2492. PubMed ID: 33217033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.
    Mackey K; King VJ; Gurley S; Kiefer M; Liederbauer E; Vela K; Sonnen P; Kansagara D
    Ann Intern Med; 2020 Aug; 173(3):195-203. PubMed ID: 32422062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Mortality Among COVID-19 Patients: A Systematic Review and Meta-Analysis.
    Kashour T; Bin Abdulhak AA; Tlayjeh H; Hassett LC; Noman A; Mohsen A; Al-Mallah MH; Tleyjeh IM
    Am J Ther; 2023 Jul-Aug 01; 30(4):e336-e346. PubMed ID: 33201001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
    COVID-19 RISk and Treatments (CORIST) Collaboration
    Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study.
    Hakeam HA; Alsemari M; Duhailib ZA; Ghonem L; Alharbi SA; Almutairy E; Sheraim NMB; Alsalhi M; Alhijji A; AlQahtani S; Khalid M; Barry M
    J Cardiovasc Pharmacol Ther; 2021 May; 26(3):244-252. PubMed ID: 33231487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis.
    Xu J; Teng Y; Shang L; Gu X; Fan G; Chen Y; Tian R; Zhang S; Cao B
    Clin Infect Dis; 2021 Jun; 72(11):e901-e913. PubMed ID: 33079200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Grover A; Oberoi M
    Eur Heart J Cardiovasc Pharmacother; 2021 Mar; 7(2):148-157. PubMed ID: 32542337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis.
    Koshy AN; Murphy AC; Farouque O; Ramchand J; Burrell LM; Yudi MB
    Intern Med J; 2020 Dec; 50(12):1468-1474. PubMed ID: 33191600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
    Xie Q; Tang S; Li Y
    Ann Palliat Med; 2022 Apr; 11(4):1253-1263. PubMed ID: 34775774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
    Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
    Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.